Get started
Work

Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

Year: 2020
Type: article
Study design: Clinical Trial
Abstract: Cabozantinib (XL184), an oral inhibitor of multiple receptor tyrosine kinases such as MET and VEGFR2, was evaluated in a phase II nonrandomized expansion study in castration-resistant prostate cancer (CRPC).
DOI: 10.17615/yxdm-6w50
Authors: Vogelzang, Nicholas J., Sweeney, Christopher J., Schimmoller, Frauke, Rathkopf, Dana E., Haas, Naomi B., Higano, Celestia S., George, Daniel J., Sartor, A. Oliver, Logothetis, Christopher J., Smith, David C., Hussain, Maha, Gordon, Michael S., Scheffold, Christian, Laird, A. Douglas, Elfiky, Aymen, Smith, Matthew R., de Bono, Johann S., Harzstark, Andrea L., Scher, Howard I., Corn, Paul G., Basch, Ethan M.
Language: English
Field: Medicine
Open Access status: green
Funders: Prostate Cancer Foundation, Bristol-Myers Squibb, Pfizer, AstraZeneca, Bayer, Sanofi, Celgene, Endocyte, Exelixis, Astellas Pharma, National Institutes of Health, Genentech, Chugai Pharmaceutical, Janssen Pharmaceuticals
OpenAlex ID: W4299419922
FWCI:
Cites:
Cited by:
Related to: 10